Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy

Journal of Vascular and Interventional Radiology

Volumn 17, Issue 2, 2006, Pages

  Brown, Daniel B ^a   Cardella, John F ^b   Sacks, David ^c   Goldberg, S Nahum ^e   Gervais, Debra A ^f   Rajan, Dheeraj ^h   Vedantham, Suresh ^a   Miller, Donald L ⁱ   Brountzos, Elias N ^j   Grassi, Clement J ^g   Towbin, Richard B ^d  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c READING HOSPITAL AND MEDICAL CENTER   (United States)

^d CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^h UNIVERSITY OF TORONTO   (Canada)

ⁱ NATIONAL CANCER INSTITUTE   (United States)

^j UNIVERSITY OF ATHENS   (Greece)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; ARTIFICIAL EMBOLISM; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COLORECTAL CARCINOMA; DRUG INFUSION; FEVER; HUMAN; IMAGING SYSTEM; INTERMETHOD COMPARISON; LEUKOCYTE COUNT; LIVER CANCER; LIVER CELL CARCINOMA; MEDICAL PRACTICE; METASTASIS; NEUROENDOCRINE TUMOR; NOMENCLATURE; PAIN; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY CONTROL; SCORING SYSTEM; TREATMENT OUTCOME; TREATMENT PLANNING; HEALTH CARE QUALITY; HEPATIC ARTERY; INTERVENTIONAL RADIOLOGY; INTRAARTERIAL DRUG ADMINISTRATION; LIVER TUMOR; MEDICAL SOCIETY; STANDARD;

ANTINEOPLASTIC AGENT; IODINATED POPPYSEED OIL;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; EMBOLIZATION, THERAPEUTIC; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; IODIZED OIL; LIVER NEOPLASMS; QUALITY ASSURANCE, HEALTH CARE; RADIOGRAPHY, INTERVENTIONAL; SOCIETIES, MEDICAL;

EID: 33746907500     PISSN: 10510443     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rvi.0000195330.47954.48     Document Type: Article

References (71)

1. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35:1164-1171.
2. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359:1734-1739.
3. Gupta S, Yao JC, Ahrar K, et al. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. Cancer J 2003; 9:261-267.
4. Salman HS, Cynamon J, Jagust M, et al. Randomized phase II trial of embolization therapy versus chemoembolization therapy in previously treated patients with colorectal carcinoma metastatic to the liver. Clin Colorectal Cancer 2002; 2:173-179.
5. Velazquez RF, Rodriguez M, Navascues CA, et al. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology 2003; 37:520-527.
6. Caturelli E, Siena DA, Fusilli S, et al. Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with cirrhosis: evaluation of damage to nontumorous liver tissue - long-term prospective study. Radiology 2000; 215:123-128.
7. Kanematsu T, Furui J, Yanaga K, et al. A 16-year experience in performing hepatic resection in 303 patients with hepatocellular carcinoma: 1985-2000. Surgery 2002; 131:153-158.
8. Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124:91-96.
9. Fisher RA, Maluf D, Cotterell AH, et al. Non-resective ablation therapy for hepatocellular carcinoma: effectiveness measured by intention-to-treat and dropout from liver transplant waiting list. Clin Transplant 2004; 18:502-512.
10. Nordlinger B, Vaillant JC, Guiguet M, et al. Survival benefit of repeat liver resections for recurrent colorectal metastases: 143 cases. Association Francaise de Chirurgie. J Clin Oncol 1994; 12:1491-1496.
11. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-2342.
12. Oberg K. Chemotherapy and biotherapy in neuroendocrine tumors. Curr Opin Oncol 1993; 5:110-120.
13. Ridolfi R, Amaducci L, Derni S, et al. Chemotherapy with 5-fluorouracil and streptozotocin in carcinoid tumors of gastrointestinal origin: experiences with 13 patients. J Chemother 1991; 3:328-331.
14. Goldberg SN, Charboneau JW, Dodd GD, et al. Image-guided tumor ablation: proposal for standardization of terms and reporting criteria. Radiology 2003; 228:335-345.
15. Singh H, Cardella JF, Cole E, et al. Quality improvement guidelines for diagnostic arteriography. J Vasc Interv Radiol 2003; 14:283S-288.
16. Pentecost MJ, Daniels JR, Teitelbaum GP, et al. Hepatic chemoembolization: safety with portal vein thrombosis. J Vasc Interv Radiol 1993; 4:347-351.
17. Chung J, Park J, Han J, et al. Hepatocellular carcinoma and portal vein invasion: results of treatment with transcatheter oily chemoembolization. AJR 1995; 165:315-321.
18. Berger DH, Carrasco CH, Hohn DC, et al. Hepatic artery chemoembolization or embolization for primary and metastatic liver tumors: post-treatment management and complications. J Surg Oncol 1995; 60:116-121.
19. Brown DB, Fundakowski CE, Lisker-Melman M, et al. Comparison of MELD and Child-Pugh scores to predict survival after chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol 2004; 15:1209-1218.
20. Stuart K, Stokes K, Jenkins R, et al. Treatment of hepatocellular carcinoma using doxorubicin/ethiodized oil/gelatin powder chemoembolization. Cancer 1993; 72:3202-3209.
21. Testa R, Testa E, Giannini E, et al. Trans-catheter arterial chemoembolisation for hepatocellular carcinoma in patients with viral cirrhosis: role of combined staging systems, Cancer Liver Italian Program (CLIP) and Model for End-stage Liver Disease (MELD), in predicting outcome after treatment. Aliment Pharmacol Ther 2003; 17:1563-1569.
22. Bruix J, Castells A, Montana X, et al. Phase II study of transarterial embolization in European patients with hepatocellular carcinoma: need for controlled trials. Hepatology 1994; 20:643-650.
23. Bruix J, Llovet JM, Castells A, et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 1998; 27:1578-1583.
24. Pelletier G, Roche A, Ink O, et al. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 1990; 11:181-184.
25. Pelletier G, Ducreux M, Gay F, et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. J Hepatol 1998; 29:129-134.
26. Barone M, Ettorre GC, Ladisa R, et al. Transcatheter arterial chemoembolization (TACE) in treatment of hepatocellular carcinoma. Hepatogastroenterology 2003; 50:183-187.
27. Ernst O, Sergent G, Mizrahi D, et al. Treatment of hepatocellular carcinoma by transcatheter arterial chemoembolization: comparison of planned periodic chemoembolization and chemoembolization based on tumor response. AJR 1999; 172:59-64.
28. Rossi S, Garbagnati F, Lencioni R, et al. Percutaneous radio-frequency thermal ablation of nonresectable hepatocellular carcinoma after occlusion of tumor blood supply. Radiology 2000; 217:119-126.
29. Yamakado K, Nakatsuka A, Ohmori S, et al. Radiofrequency ablation combined with chemoembolization in hepatocellular carcinoma: treatment response based on tumor size and morphology. J Vasc Interv Radiol 2002; 13:1225-1232.
30. Li YH, Wang CS, Liao LY, et al. Long-term survival of Taiwanese patients with hepatocellular carcinoma after combination therapy with transcatheter arterial chemoembolization and percutaneous ethanol injection. J Formos Med Assoc 2003; 102:141-146.
31. Brown KT, Koh BY, Brody LA, et al. Particle embolization of hepatic neuroendocrine metastases for control of pain and hormonal symptoms. J Vasc Interv Radiol 1999; 10:397-403.
32. Gray B, Van Hazel G, Hope M, et al. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 2001; 12:1711-1720.
33. Mavligit GM, Charnsangavej C, Carrasco CH, et al. Regression of ocular melanoma metastatic to the liver after hepatic arterial chemoembolization with cisplatin and polyvinyl sponge. JAMA 1988; 260:974-976.
34. Rajan DK, Soulen MC, Clark TW, et al. Sarcomas metastatic to the liver: response and survival after cisplatin, doxorubicin, mitomycin-C, Ethiodol, and polyvinyl alcohol chemoembolization. J Vasc Interv Radiol 2001; 12:187-193.
35. Mavligit GM, Zukwiski AA, Ellis LM, et al. Gastrointestinal leiomyosarcoma metastatic to the liver: durable tumor regression by hepatic chemoembolization infusion with cisplatin and vinblastine. Cancer 1995; 75:2083-2088.
36. Bedikian AY, Legha SS, Mavligit G, et al. Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors. Cancer 1995; 76:1665-1670.
37. Reed RA, Teitelbaum GP, Daniels JR, et al. Prevalence of infection following hepatic chemoembolization with cross-linked collagen with administration of prophylactic antibiotics. J Vasc Interv Radiol 1994; 5:367-371.
38. Ryan JM, Ryan BM, Smith TP. Antibiotic prophylaxis in interventional radiology. J Vasc Interv Radiol 2004; 15:547-556.
39. Kim W, Clark TWI, Baum RA, et al. Risk factors for liver abscess formation after hepatic chemoembolization. J Vasc Interv Radiol 2001; 12:965-968.
40. Geschwind JF, Kaushik S, Ramsey DE, et al. Influence of a new prophylactic antibiotic therapy on the incidence of liver abscesses after chemoembolization treatment of liver tumors. J Vasc Interv Radiol 2002; 13:1163-1166.
41. Covey AM, Brody LA, Maluccio MA, et al. Variant hepatic arterial anatomy revisited: digital subtraction angiography performed in 600 patients. Radiology 2002; 224:542-547.
42. Chung J, Park J, Han J, et al. Transcatheter oily chemoembolization of the inferior phrenic artery in hepatocellular carcinoma: the safety and potential therapeutic role. J Vasc Interv Radiol 1998; 9:495-500.
43. Kim JH, Chung JW, Han JK, et al. Transcatheter arterial embolization of the internal mammary artery in hepatocellular carcinoma. J Vasc Interv Radiol 1995; 6:71-74.
44. Tajima T, Honda H, Kuroiwa T, et al. Pulmonary complications after hepatic artery chemoembolization or infusion via the inferior phrenic artery for primary liver cancer. J Vasc Interv Radiol 2002; 13:893-900.
45. Arora R, Soulen M, Haskal Z. Cutaneous complications of hepatic chemoembolization via extrahepatic collaterals. J Vasc Interv Radiol 1999; 10:1351-1356.
46. Leung DA, Goin JE, Sickles C, et al. Determinants of postembolization syndrome after hepatic chemoembolization. J Vasc Interv Radiol 2001; 12:321-326.
47. Hartnell GG, Gates J, Stuart K, et al. Hepatic chemoembolization: effect of intraarterial lidocaine on pain and postprocedure recovery. Cardiovasc Intervent Radiol 1999; 22:293-297.
48. Lee SH, Hahn ST, Park SH. Intraarterial lidocaine administration for relief of pain resulting from transarterial chemoembolization of hepatocellular carcinoma: its effectiveness and optimal timing of administration. Cardiovasc Intervent Radiol 2001; 24:368-371.
49. Camma C, Schepis F, Orlando A, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002; 224:47-54.
50. Maeda S, Fujiyama S, Tanaka M, et al. Survival and local recurrence rates of hepatocellular carcinoma patients treated by transarterial chemolipiodolization with and without embolization. Hepatol Res 2002; 23:202-210.
51. Ikeda M, Maeda S, Shibata J, et al. Transcatheter arterial chemotherapy with and without embolization in patients with hepatocellular carcinoma. Oncology 2004; 66:24-31.
52. Higuchi T, Kikuchi M, Okazaki M. Hepatocellular carcinoma after transcatheter hepatic arterial embolization: a histopathologic study of 84 resected cases. Cancer 1994; 73:2259-2267.
53. Takayasu K, Arii S, Matsuo N, et al. Comparison of CT findings with resected specimens after chemoembolization with iodized oil for hepatocellular carcinoma. AJR 2000; 175:699-704.
54. Kubota K, Hisa N, Nishikawa T, et al. Evaluation of hepatocellular carcinoma after treatment with transcatheter arterial chemoembolization: comparison of Lipiodol-CT, power Doppler sonography, and dynamic MRI. Abdom Imaging 2001; 26:184-190.
55. Chopra S, Dodd GD, Chintapalli KN, et al. Tumor recurrence after radiofrequency thermal ablation of hepatic tumors: spectrum of findings on dualphase contrast-enhanced CT. AJR 2001; 177:381-387.
56. Brown KT, Nevins AB, Getrajdman GI, et al. Particle embolization for hepatocellular carcinoma. J Vasc Interv Radiol 1998; 9:822-828.
57. Solomon B, Soulen M, Baum R, et al. Chemoembolization of hepatocellular carcinoma with cisplatin, doxorubicin, mitomycin-C, Ethiodol, and polyvinyl alcohol: prospective evaluation of response and survival in a U.S. population. J Vasc Interv Radiol 1999; 10:793-798.
58. Leichman CG, Jacobson JR, Modiano M, et al. Hepatic chemoembolization combined with systemic infusion of 5-fluorouracil and bolus leucovorin for patients with metastatic colorectal carcinoma: a Southwest Oncology Group pilot trial. Cancer 1999; 86:775-781.
59. Martinelli DJ, Wadler S, Bakal CW, et al. Utility of embolization or chemoembolization as second-line treatment in patients with advanced or recurrent colorectal carcinoma. Cancer 1994; 74:1706-1712.
60. Sanz-Altamira PM, Spence LD, Huberman MS, et al. Selective chemoembolization in the management of hepatic metastases in refractory colorectal carcinoma: a phase II trial. Dis Colon Rectum 1997; 40:770-775.
61. Tellez C, Benson AB, Lyster MT, et al. Phase II trial of chemoembolization for the treatment of metastatic colorectal carcinoma to the liver and review of the literature. Cancer 1998; 82:1250-1259.
62. Popov I, Lavrnic S, Jelic S, et al. Chemoembolization for liver metastases from colorectal carcinoma: risk or a benefit. Neoplasma 2002; 49:43-48.
63. Hunt TM, Flowerdew AD, Birch SJ, et al. Prospective randomized controlled trial of hepatic arterial embolization or infusion chemotherapy with 5-fluorouracil and degradable starch microspheres for colorectal liver metastases. Br J Surg 1990; 77:779-782.
64. Kim YH, Ajani JA, Carrasco CH, et al. Selective hepatic arterial chemoembolization for liver metastases in patients with carcinoid tumor or islet cell carcinoma. Cancer Invest 1999; 17:474-478.
65. Clouse ME, Perry L, Stuart K, et al. Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Digestion 1994; 55(suppl 3):92-97.
66. Gates J, Hartnell GG, Stuart KE, et al. Chemoembolization of hepatic neoplasms: safety, complications, and when to worry. Radiographics 1999; 19:399-414.
67. Song SY, Wook CJ, Koo J, et al. Liver abscess after transcatheter oily chemoembolization for hepatic tumors: incidence, predisposing factors, and clinical outcome. J Vasc Interv Radiol 2001; 12:313-320.
68. Sakamoto I, Aso N, Nagaoki K, et al. Complications associated with transcatheter arterial embolization for hepatic tumors. Radiographics 1998; 18:605-619.
69. Chung J, Park J, Han J, et al. Hepatic tumors: predisposing factors for complications of transcatheter oily chemoembolization. Radiology 1996; 198:33-40.
70. Fink A, Kosecoff J, Chassin M, et al. Consensus methods: characteristics and guidelines for use. Am J Public Health 1984; 74:979-983.
71. Leape LL, Hilborne LH, Park RE, et al. The appropriateness of use of coronary artery bypass graft surgery in New York State. JAMA 1993; 269:753-760.